Effect of interferon-γ in experimental Cryptosporidium parvum infection

Journal of Infectious Diseases

Volumn 174, Issue 1, 1996, Pages 229-232

  Rehg, Jerold E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILIARY TRACT DISEASE; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DIARRHEA; DOSE RESPONSE; HOST RESISTANCE; IMMUNOCOMPETENT CELL; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RAT;

EID: 0030055601     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.1.229     Document Type: Article

References (15)

1. Current WL, Garcia LS. Cryptosporidiosis. Clin Microbiol Rev 1991;4:325-58.
2. Gomez Morales MA, Ausiello CM, Urbani F, Pozio E. Crude extract and recombinant protein of Cryptosporidium parvum oocysts induce proliferation of human peripheral blood mononuclear cells in vitro. J Infect Dis 1995;172:211-6.
3. Murray HW, Rubin BY, Masur H, Roberts RB. Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome. N Engl J Med 1984;310:883-9.
4. + cells in response to Cryptosporidium parvum antigen. J Parasitol 1994;80:67-72.
5. + T lymphocytes in protective immunity. J Immunol 1991;147:1014-22.
6. McCabe RE, Luft BJ, Remington JS. Effect of murine interferon gamma on murine toxoplasmosis. J Infect Dis 1984;150:961-2.
7. Shear HL, Valladares G, Narachi MA. Enhanced treatment of Pneumocystis carinii pneumonia in rats with interferon and reduced doses of trimethoprim/sulfamethoxazole. J Acquir Immune Defic Syndr 1990;3:943-8.
8. Rehg JE, Hancock ML, Woodmansee DB. Characterization of a dexamethasone-treated rat model of cryptosporidial infection. J Infect Dis 1988;158:1406-7.
9. Rehg JE, Hancock ML, Woodmansee DB. Characterization of cyclophosphamide-rat model of cryptosporidiosis. Infect Immun 1987;55:2669-74.
10. Murray HW. Effect of continuous administration of interferon-γ in experimental visceral leishmaniasis. J Infect Dis 1990;161:992-4.
11. Kuhls TL, Mosier DA, Abrams VL, Crawford DL, Greenfield RA. Inability of interferon-gamma and aminoguanidine to alter Cryptosporidium parvum infection in mice with severe combined immunodeficiency. J Parasitol 1994;80:480-5.
12. Kurzrock R, Rosenblum MG, Sherwin SA, et al. Pharmacokinetics, single-dose tolerance, and biological activity of recombinant-interferon in cancer patients. Cancer Res 1985;45:2866-72.
13. Rasmussen KR, Martin EG, Arrowood MJ, Healey MC. Effects of dexamethasone and dehydroepiandrosterone in immunosuppressed rats infected with Cryptosporidium parvum. J Protozool 1991;38:157S-9S.
14. Hofflin JM, Remington JS. In vivo synergism of roxithromycin (RU 965) and interferon against Toxoplasma gondii. Antimicrob Agents Chemother 1987;31:346-8.
15. Heagy W, Groopman J, Schindler J, Finberg R. Use of IFN-γ in patients with AIDS. J Acquir Immune Defic Syndr 1990;3:584-90.